Ipsogen has launched MapQuant Dx HER2 test. Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.
Launch Diagnostics provides complete pathology solutions with a comprehensive portfolio of high-quality diagnostic reagents and instrumentation from world leading manufacturers to the Health Services of the United Kingdom. Our associated companies also provide solutions to France, Belgium, and Luxemburg through Launch Diagnostics SAS, to the...
ACV, Vienna, Austria
6 -10 September, 2025
The International Convention Centre (ICC), Birmingham
22-25 September, 2025
The Catalyst, Newcastle
3 October
Manchester Conference Centre
8 October
Online
11-13 November, 2025
